Elicio Therapeutics, Inc.
ELTX
$2.18
-$0.17-7.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.13% | 18.04% | 13.08% | 0.16% | -1.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.07% | -17.37% | -16.16% | 3.54% | 8.03% |
| Operating Income | 15.07% | 17.37% | 16.16% | -3.54% | -8.03% |
| Income Before Tax | 30.71% | 21.64% | 23.75% | 2.10% | -41.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.71% | 21.64% | 23.75% | 2.10% | -41.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.71% | 21.64% | 23.75% | 2.10% | -41.25% |
| EBIT | 15.07% | 17.37% | 16.16% | -3.54% | -8.03% |
| EBITDA | 14.97% | 17.27% | 16.02% | -3.75% | -8.25% |
| EPS Basic | 44.67% | 38.54% | 37.57% | 25.40% | 4.28% |
| Normalized Basic EPS | 45.03% | 37.88% | 36.96% | 25.01% | 3.65% |
| EPS Diluted | 44.67% | 38.54% | 37.57% | 25.40% | 4.28% |
| Normalized Diluted EPS | 45.03% | 37.88% | 36.96% | 25.01% | 3.65% |
| Average Basic Shares Outstanding | 23.85% | 29.15% | 25.45% | 35.87% | 46.17% |
| Average Diluted Shares Outstanding | 23.85% | 29.15% | 25.45% | 35.87% | 46.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |